Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01932801 · ClinicalTrials.gov registry record · Phase 2
Harm Reduction With Pharmacotherapy (HaRP)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 308
- Enrollment target
NCT01932801 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 308 participants.
The verdict
NCT01932801, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 308 participants
- Enrollment target
Study Summary
The goal of this study is to test the efficacy of extended-release naltrexone and harm reduction counseling in reducing alcohol-related harm among homeless people with alcohol dependence.
Interventions
- OTHER Placebo
- DRUG XR-NTX
- BEHAVIORAL HRC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 308 participants |
| Start Date | 2013-08-01 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01932801
The ClinicalTrials.gov registry entry for NCT01932801 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 308 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01932801 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01932801 about?
NCT01932801 is a clinical study titled "Harm Reduction With Pharmacotherapy (HaRP)". The goal of this study is to test the efficacy of extended-release naltrexone and harm reduction counseling in reducing alcohol-related harm among homeless people with alcohol dependence.
What is the current status of trial NCT01932801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 308 participants. The study started on 2013-08-01. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT01932801?
The interventions under investigation include: Placebo (OTHER), XR-NTX (DRUG), HRC (BEHAVIORAL).
Who is sponsoring clinical trial NCT01932801?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.